Copertina

Letter: Role of Helicobacter pylori and metabolic syndrome‐related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH—Authors’ reply

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	S. K. Bansal, M. B. Bansal
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter: Role of Helicobacter pylori and metabolic syndrome‐related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH
di: Jannis Kountouras, et al.
Pubblicazione: (2024)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
di: Kyle Staller, et al.
Pubblicazione: (2024)

Letter: Helicobacter pylori and Eosinophilic Oesophagitis—Lost in Definition? Authors' Reply
di: Irene Spinelli, et al.
Pubblicazione: (2025)

Letter: Association between terlipressin and multidrug‐resistant organism rectal colonization: Authors' reply
di: Marcus M. Mücke, et al.
Pubblicazione: (2024)

Letter: Potential impact ofHelicobacter pyloriinfection on oesophageal disorders in chronic liver disease—Authors' reply
di: Francisco Idalsoaga, et al.
Pubblicazione: (2024)

Letter: Helicobacter pylori and metabolic syndrome‐related von Willebrand factor and plasminogen activator inhibitor‐1 activity levels for outcome prediction of advanced chronic liver disease
di: Jannis Kountouras, et al.
Pubblicazione: (2024)

Letter: Helicobacter pylori and Eosinophilic Oesophagitis—Lost in Definition?
di: Fernanda Cristofori, et al.
Pubblicazione: (2025)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—an emulated clinical trial. Authors' reply
di: Elliot B. Tapper, et al.
Pubblicazione: (2024)

Letter: Disappearing Microbe, Emerging Disease? Nuancing the Protective Effects of Helicobacter pylori Against Eosinophilic Oesophagitis. Authors' Reply
di: Irene Spinelli, et al.
Pubblicazione: (2025)

Letter: The enigma of angiotensin receptor blocker‐associated enteropathy—Authors' reply
di: Annalisa Schiepatti, et al.
Pubblicazione: (2024)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
di: Stuart McPherson, et al.
Pubblicazione: (2024)

Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply
di: Matthias Lenfant, et al.
Pubblicazione: (2024)

Letter: Thioguanine, an under‐utilised option in inflammatory bowel disease? Authors' reply
di: Abhinav Vasudevan, et al.
Pubblicazione: (2024)

Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights. Authors' reply
di: Matthias Lenfant, et al.
Pubblicazione: (2024)

Letter: Dietary emulsifiers and intestinal health—The beginning of an evolving story: Authors’ reply
di: Jessica A. Fitzpatrick, et al.
Pubblicazione: (2024)

Letter: Resmetirom for treatment of MASH with children and adolescents
di: Yong‐Hai Zhou, et al.
Pubblicazione: (2024)

Letter: Bif195 for aspirin‐induced gastric mucosal damage – More to do in further research. Authors' reply
di: Nina Løn, et al.
Pubblicazione: (2024)

Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease
di: Jannis Kountouras, et al.
Pubblicazione: (2024)

Letter: Meta‐Analysis Critique: Refining the Association Between Helicobacter pylori and Eosinophilic Oesophagitis
di: Haleema Rahman
Pubblicazione: (2025)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply
di: Hyeyeon Hong, et al.
Pubblicazione: (2024)

Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD—Authors' reply
di: Arta Aliu, et al.
Pubblicazione: (2024)

Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis—Authors' reply
di: David Bergman, et al.
Pubblicazione: (2024)

Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis—Authors' reply
di: Lukas Burghart, et al.
Pubblicazione: (2024)

Letter: Social work and clinical synergy—Optimizing health interventions for elderly DGBI populations: Authors' reply
di: Ami D. Sperber, et al.
Pubblicazione: (2024)

Letter: Beyond advanced fibrosis—The critical need for assessing NITs performance in identifying F2‐F3 fibrosis. Authors' reply
di: Stuart McPherson, et al.
Pubblicazione: (2024)

Editorial: Quantity is important! Authors' reply
di: Marika Rudler, et al.
Pubblicazione: (2024)

Letter: Disappearing Microbe, Emerging Disease? Nuancing the Protective Effects of Helicobacter pylori Against Eosinophilic Oesophagitis
di: Enzo Emanuele, et al.
Pubblicazione: (2025)

Letter: Third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions—Authors' reply
di: María José García, et al.
Pubblicazione: (2024)

Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find. Author's reply
di: Sagnik Biswas, et al.
Pubblicazione: (2024)

Letter: Enhancing gastric cancer prevention—The need for a comprehensive three‐tier emergency management strategy. Authors' reply
di: Irene Ligato, et al.
Pubblicazione: (2024)

Editorial: The microbiome and gastric mucosal protection in aspirin users—Authors' reply
di: Nina Løn, et al.
Pubblicazione: (2024)

Editorial: Another brick in the CDST wall: Authors' reply
di: Kyuwon Kim, et al.
Pubblicazione: (2024)

Letter: Critical appraisal of biologic therapy in early ulcerative colitis management—Addressing study limitations and the role of psychological resilience—Authors' reply
di: Vibeke Strande, et al.
Pubblicazione: (2024)

Letter: Ulcerative proctitis—A step towards addressing the knowledge gap, and a call for greater detail, in trial data—Authors' reply
di: Rocío Ferreiro‐Iglesias, et al.
Pubblicazione: (2024)

Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed. Authors' reply
di: Andrea Martini, et al.
Pubblicazione: (2024)

Editorial: Sonographic assessment of colonic content—A new tool for constipation? Authors' reply
di: R. M. Mathias, et al.
Pubblicazione: (2024)

Letter: Selective FGFR1c/KLB Activation in MASH—A Mechanistic Dilemma?
di: Cuiyun Tao, et al.
Pubblicazione: (2025)

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity? Authors' Reply
di: Eric Lawitz, et al.
Pubblicazione: (2025)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
di: Carolin V. Schneider, et al.
Pubblicazione: (2024)

Editorial: Recompensation in PBC is good. But is it good enough? Authors' reply
di: Benedikt Silvester Hofer, et al.
Pubblicazione: (2024)